98%
921
2 minutes
20
Importance: Over the last 2 decades, bronchiolitis guidelines and improvement efforts focused on supportive care and reducing unnecessary tests, treatments, and hospitalization. There have been limited population-based studies examining hospitalization outcomes over time.
Objective: To describe rates and trends in bronchiolitis hospitalization, intensive care unit (ICU) use, mortality, and costs.
Design, Setting, And Participants: This cohort study used population-based health administrative data from April 1, 2004, to March 31, 2018, to identify bronchiolitis encounters using hospital discharge diagnosis codes in Ontario, Canada. Children younger than 2 years with and without bronchiolitis hospitalization were included. Data were analyzed from January 2020 to July 2021.
Main Outcomes And Measures: Bronchiolitis hospitalization per 1000 person-years, ICU use per 1000 hospitalizations, mortality per 100 000 person-years, and costs per 1000 person-years adjusted to 2018 Canadian dollars and reported in 2018 US dollars.
Results: Among 2 336 446 included children, 1 199 173 (51.3%) were male. During the study period, 43 993 children (1.9%) younger than 2 years had 48 058 bronchiolitis hospitalizations at 141 hospitals. Bronchiolitis accounted for 48 058 of 360 920 all-cause hospitalizations (13.3%) and 215 654 of 2 566 348 all-cause hospital days (8.4%) in children younger than 2 years. Bronchiolitis hospitalization was stable over time, at 14.0 (95% CI, 13.6-14.4) hospitalizations per 1000 person-years in 2004-2005 and 12.7 (95% CI, 12.2-13.1) hospitalizations per 1000 person-years in 2017-2018 (annual percent change [APC], 0%; 95% CI, -1.6 to 1.6; P = .97). ICU admission increased significantly from 38.1 (95% CI, 32.2-44.8) per 1000 hospitalizations in 2004-2005 to 87.8 (95% CI, 78.3-98.0) per 1000 hospitalizations in 2017-2018 (APC, 7.2%; 95% CI, 5.4-8.9; P < .001). Over the study period, bronchiolitis mortality was 2.8 (95% CI, 2.3-3.4) per 100 000 person-years and remained stable (APC, 1.1%; 95% CI, -8.4 to 11.7; P = .85). Hospitalization costs per 1000 person-years increased from $49 640 (95% CI, $49 617-$49 663) in 2004-2005 to $58 632 (95% CI, $58 608-$58 657) in 2017-2018 (APC, 3.0%; 95% CI, 1.3-4.8; P = .002).
Conclusions And Relevance: From 2004 to 2018, bronchiolitis hospitalization and mortality rates remained stable; however, ICU use and costs increased substantially. This represents a major increase in high-intensity hospital care and costs for one of the most common and cumulatively expensive conditions in pediatric hospital care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689435 | PMC |
http://dx.doi.org/10.1001/jamapediatrics.2021.5177 | DOI Listing |
Indian J Pediatr
September 2025
Department of Pharmaceutical Sciences, GC University, Lahore, Pakistan.
Hosp Pediatr
September 2025
Division of Hospital Medicine, Children's National Hospital, Washington, District of Columbia.
Objective: To describe institutional variation in standardized order set (SOS) utilization and SOS infrastructure within a regional pediatric care network.
Patients And Methods: This preliminary cross-sectional study explores SOS utilization and infrastructure at 5 pediatric hospital medicine services across a regional network. SOS utilization was calculated as the proportion of patient encounters where a diagnosis-based SOS was used for patients admitted with a diagnosis of asthma, bronchiolitis, skin and soft tissue infection, gastroenteritis, or pneumonia between July 1, 2019, and June 30, 2023.
Respir Med
September 2025
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Hematopoietic stem cell transplant (HSCT) is a cornerstone for the treatment of high-risk hematologic malignancies. The efficacy of HSCT is limited by transplant-related complications, particularly pulmonary complications. Broadly speaking, the myriads of non-infectious complications that occur after HSCT are less completely understood than infectious complications despite contributing to significant morbidity and mortality.
View Article and Find Full Text PDFmedRxiv
August 2025
Department of Sleep and Respiratory Medicine, Perth Children's Hospital, Perth, Western Australia, Australia.
Background: Early-life susceptibility to viral respiratory infections is associated with long-term respiratory morbidity in children. Currently, no reliable tools exist to predict susceptibility to these infections. Given its role in modulating pathogen virulence and airway inflammation, the endogenous microbiota represents a potential target for prevention.
View Article and Find Full Text PDFJHLT Open
November 2025
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Respiratory viruses encompass a diverse group of viruses, including influenza, respiratory syncytial virus (RSV), parainfluenza (PIV), human metapneumovirus (hMPV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and adenovirus. Lung transplant recipients are particularly vulnerable to complications from respiratory viral infections (RVIs), leading to increased morbidity and mortality. This heightened risk is a result of both anatomical and functional modifications from transplant surgery, as well as immunosuppressive therapy.
View Article and Find Full Text PDF